EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Prophylactic cancer vaccines: development and challenges for HBV and HPV vaccines in Latin America

Laura Ximena Ramírez-López, Martha Carnalla-Cortés, Tonatiuh Barrientos-Gutiérrez, Pierre Coursaget, Nubia Muñoz

Salud Pública de México · 2023

DOI: 10.21149/15061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Salud Pública de México, 2023. Verfasst von Laura Ximena Ramírez-López und 4 weiteren Autor:innen. Beteiligte Einrichtung: Facultad Ciencias de la Salud, Universidad de Boyacá. Tunja, Colombia. Doctorado en Salud Pública, Escuela de Salud Pública de México. Cuernavaca, Mo…. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Cancer Vaccines, Papillomavirus Infections, Uterine Cervical Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccines against hepatitis B virus (HBV) and human papillomaviruses (HPV) are two safe and highly effective vaccines that were developed at the end of the 20th century and can prevent human cancer. HBV vaccine prevents liver cancer, and HPV prevents cervical and other HPV-related cancers. Starting with the immunogen identification, 15 years were necessary to reach the industrial production of HBV vaccine, and 20 years, for the HPV vaccines. However, while HBV vaccines have been commercially available for over 40 years and are used in most countries, there are still significant challenges to achieve universal childhood immunization against hepatitis B. Similarly, HPV vaccines have been commercially available for 17 years, and yet, countries with higher cervical cancer still have the lowest HPV vaccination rates. We describe the development of HBV and HPV vaccines and discuss the challenges to reaching equitable access to these vaccines in Latin America.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus VaccinesCancer VaccinesPapillomavirus InfectionsUterine Cervical NeoplasmsFemaleHumansChildHepatitis B virusLatin AmericaVaccinationHepatitis B Vaccines

Substanzen

Papillomavirus VaccinesCancer VaccinesHepatitis B Vaccines

Autor:innen und Institutionen

  • Facultad Ciencias de la Salud, Universidad de Boyacá. Tunja, Colombia. Doctorado en Salud Pública, Escuela de Salud Pública de México. Cuernavaca, Morelos, Mexico.. laura.ramirez@insp.edu.mx.
  • Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.. mcarnalla@gmail.com.
  • Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico.. tbarrientos@insp.mx.
  • Faculté des Sciences Pharmaceutiques, Université F Rabelais. Tours, France.. pcoursaget@wanadoo.fr.
  • Independent consultant. Lyon, France.. nubiamunoz@gmail.com.

Zitieren

APA

Ramírez-López, L. X., Carnalla-Cortés, M., Barrientos-Gutiérrez, T., Coursaget, P., & Muñoz, N. (2023). Prophylactic cancer vaccines: development and challenges for HBV and HPV vaccines in Latin America. Salud Pública de México. https://doi.org/10.21149/15061

Vancouver

Ramírez-López LX, Carnalla-Cortés M, Barrientos-Gutiérrez T, Coursaget P, Muñoz N. Prophylactic cancer vaccines: development and challenges for HBV and HPV vaccines in Latin America. Salud Pública de México. 2023. doi:10.21149/15061

BibTeX
@article{RamrezLpez2023,
  author = {Ramírez-López, Laura Ximena and Carnalla-Cortés, Martha and Barrientos-Gutiérrez, Tonatiuh and Coursaget, Pierre and Muñoz, Nubia},
  title = {Prophylactic cancer vaccines: development and challenges for HBV and HPV vaccines in Latin America},
  journal = {Salud Pública de México},
  year = {2023},
  doi = {10.21149/15061}
}
Kostenlos starten →